Insmed shares deliver 41.43% annualized return over five years
Insmed has generated a 41.43% average annual return over the last five years, outperforming the market by 29.76%. A $1,000 investment from five years ago is now valued at $5,573.37 at the current price of $131.95. The company’s market capitalization stands at $28.82 billion, illustrating significant long-term wealth creation for shareholders through compounded growth.
*this image is generated using AI for illustrative purposes only.
Insmed (NASDAQ: INSM) has significantly outperformed the broader market over the past five years, delivering an average annual return of 41.43%. This performance represents a 29.76% annualized outperformance relative to market benchmarks. As of the time of writing, the company holds a market capitalization of $28.82 billion, reflecting sustained investor confidence and substantial value creation for shareholders holding positions over this multi-year period.
The magnitude of this growth is illustrated by the trajectory of a hypothetical long-term investment. An investor who purchased $1,000 worth of Insmed stock five years ago would see that position grow to $5,573.37 today. This calculation is based on the current trading price of $131.95 per share. The data underscores the impact of compounded returns on capital growth over extended time horizons, demonstrating how consistent annual gains can multiply initial principal amounts substantially.
Investment Performance Metrics
The following table details the key performance indicators for Insmed stock over the specified five-year period:
| Metric | Value |
|---|---|
| Initial Investment | $1,000 |
| Current Value | $5,573.37 |
| Average Annual Return | 41.43% |
| Market Outperformance | 29.76% |
| Current Share Price | $131.95 |
| Market Capitalization | $28.82 billion |
What the Numbers Show
The disparity between the initial investment of $1,000 and the current value of $5,573.37 highlights the exponential nature of the company’s stock price appreciation. With an annualized return of 41.43%, Insmed’s growth rate has been more than four times the initial principal amount annually on average. This level of outperformance, exceeding the market by nearly 30 percentage points annually, suggests that Insmed has captured significant alpha during this period, likely driven by strong fundamental developments or sector-specific tailwinds that are not present in broader market indices.
What specific clinical milestones or product approvals are expected to drive Insmed's growth trajectory in the next 12 to 24 months?
Can Insmed sustain its current 41.43% annualized return given its $28.82 billion market capitalization, or is a normalization of returns likely?
How does Insmed's current valuation compare to its peers in the biopharma sector, and does this suggest the stock is overvalued relative to future cash flows?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
